World Markets

FDA puts partial hold on clinical trials of AbbVie's cancer drug

Reuters

March 19 () - AbbVie Inc said on Tuesday the U.S. Food and Drug Administration placed a partial clinical hold on all trials of its cancer drug Venclexta for multiple myeloma, after a review of data found a higher proportion of deaths in the Venclexta arm of the late-stage study.

Data review from the trial showed a higher number of deaths among patients taking Venclexta, compared to those given a placebo alongside other treatment.

However, the clinical hold does not impact any of the approved indications for Venclexta, and is limited to investigational clinical trials in multiple myeloma, AbbVie said.

The drug is already approved to treat other types of cancer, including chronic lymphocytic leukemia and acute myeloid leukemia. It brought in $344 million revenue for AbbVie in 2018.

Venclexta is jointly sold by AbbVie and Roche AG in the United States, while AbbVie sells it in other markets.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

ABBV

Other Topics

Stocks Technology

Reuters

Reuters, the news and media division of Thomson Reuters, is the world’s largest international multimedia news provider reaching more than one billion people every day. Reuters provides trusted business, financial, national, and international news to professionals via Thomson Reuters desktops, the world's media organizations, and directly to consumers at Reuters.com and via Reuters TV.

Learn More